Antibodies Inc. Unveils Recombinant RBPMS Antibody for Retinal Research

Antibodies Inc., a well-known supplier of life science research reagents, has recently introduced its Recombinant Guinea Pig RBPMS Antibody (Clone OTI3B7-GP, Cat. No. 1834-RBPMS). This groundbreaking product is designed to enhance research on retinal ganglion cells (RGCs) by providing unmatched reproducibility, specificity, and performance.

The antibody is categorized under the PhosphoSolutions brand, which has a proven history of delivering high-performance neuroscience reagents. The release of this recombinant version is a significant upgrade from the previously offered guinea pig polyclonal RBPMS Antibody (Cat. No. 1832-RBPMS), addressing several limitations associated with traditional formats.

Understanding RBPMS and Its Significance

RBPMS, or RNA Binding Protein with Multiple Splicing, has become a gold-standard marker for identifying retinal ganglion cells. Its accurate identification is crucial in both vision research and studies related to neurodegeneration. Historically, guinea pig polyclonal antibodies offered some advantages in multiplex immunofluorescence. However, these traditional antibodies have faced challenges, such as lot-to-lot variability and limited supply.

The newly launched Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) effectively overcomes these issues through recombinant engineering. By eliminating concerns about variability between production batches and ensuring a steady supply, this antibody provides consistent and reliable results. The design integrates the well-validated antigen-binding region from the OTI3B7 clone with a guinea pig IgG constant region. This allows for seamless multiplexing with mouse and rabbit antibodies and offers long-term consistency across various studies.

Key Benefits of the Recombinant RBPMS Antibody

Antibodies Inc. emphasizes several notable advantages of the Recombinant Guinea Pig RBPMS Antibody, including:
1. State-of-the-Art Identification: The antibody serves as an exemplary tool for identifying retinal ganglion cells, a vital aspect of ocular research.
2. Multiplex Immunolabeling: Leveraging the guinea pig format enables advanced multiplex immunolabeling techniques, broadening the scope of research applications.
3. Defined Amino Acids: The OTI3B7-GP clone boasts a well-characterized amino acid sequence, contributing to reliable experiment outcomes.
4. Ethically Produced: The antibody is produced without animal serum, ensuring animal-free manufacturing practices.
5. Reproducibility: The antibody ensures lot-to-lot reproducibility, making it ideal for longitudinal studies and facilitating consistency across multiple research sites.

This antibody has been validated for use in both immunohistochemistry (IHC) and Western blotting techniques, providing researchers with clear and specific labeling of retinal ganglion cells in various mammalian tissue samples.

Commitment to Scientific Advancement

The launch of the Recombinant Guinea Pig RBPMS Antibody reflects Antibodies Inc.’s deeper dedication to advancing scientific discoveries. Their growing portfolio of specialized brands, including PhosphoSolutions, allows them to deliver the innovative tools necessary for modern research.

Researchers interested in learning more can access the full PhosphoSolutions product line through Antibodies Inc.'s website, where additional resources and authoritative guidance on the Recombinant Guinea Pig RBPMS Antibody are also available.

In conclusion, the Recombinant Guinea Pig RBPMS Antibody is set to revolutionize retinal research, establishing a new benchmark for antibody performance and reliability. It is now readily available for purchase through Antibodies Inc. and authorized global distributors, ensuring that researchers worldwide can benefit from this significant advancement in research reagents.

For more information on the Recombinant Guinea Pig RBPMS Antibody and other products, please visit Antibodies Inc..